Regulatory Roundup: FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA released this week a final guidance on anticounterfeiting excipients. The guidance recommends that any physical–chemical identifier incorporated into solid oral dosage forms of drugs be pharmacologically inactive. Quality, potency, and bioavailability are also discussed.

FDA, the Centers for Medicare (CMS), and Medicaid launched a pilot program last week to conduct parallel reviews of medical devices, which are seeking FDA approval as well as Medicare coverage. “The FDA and CMS anticipate that parallel review will facilitate the development of innovative new products and increase the efficiency of the review processes for both agencies,” according to an agency press release. The two-year pilot is voluntary and will not change the existing separate and distinct review standards for FDA device approval and CMS coverage determination.

FDA also announced a joint study with NIH on tobacco use and risk. The large-scale, national study will monitor tobacco users to assess the behavioral and health impacts of new government tobacco regulations, namely the 2009 Family Smoking Prevention and Tobacco Control.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here